Avinger (AVGR) Trading 2.9% Higher

Avinger Inc (NASDAQ:AVGR) shares traded up 2.9% during mid-day trading on Thursday . The company traded as high as $0.37 and last traded at $0.35. 220,769 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 1,404,119 shares. The stock had previously closed at $0.34.

Separately, Zacks Investment Research raised shares of Avinger from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a report on Tuesday, November 20th.

Avinger (NASDAQ:AVGR) last posted its quarterly earnings results on Tuesday, November 13th. The medical device company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.05). The business had revenue of $2.02 million for the quarter. Equities research analysts predict that Avinger Inc will post -7.19 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/12/08/avinger-avgr-trading-2-9-higher.html.

Avinger Company Profile (NASDAQ:AVGR)

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Further Reading: What is a conference call?

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply